Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
DBV Technologies
DBV Technologies
Activities:
Drug Delivery
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Recruitment
DBV Technologies makes major changes to its Board of Directors
Replacing the retiring co-founder, Michel de Rosen has been appointed as new Non-Executive Chairman of the Board. Company CEO, Daniel Tassé, has also been appointed to the Board
Pharmaceutical
DBV Technologies welcomes Dr Lucia Septien as Chief Medical Officer
Septien was most recently Vice President, Global Neurosciences at Ipsen
Pharmaceutical
DBV Technologies welcomes Edward Jordan as SVP Commercial Operations North America
As the biopharmaceutical firm prepares for the commercialisation of products to treat food allergies
Subscribe now